RxDoctor Payments Data

Michael Kerner, MD

Gastroenterology · Springfield, NJNPI 1982693990

Payments from drug & device makers

$4,170in general payments, 2019–2025

Across 196 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$470
  • Pfizer$332
  • Takeda Pharmaceuticals U.S.A., Inc.$286
  • E.r. Squibb & Sons, L.L.C.$245
  • Johnson & Johnson$174
  • plus $494 from 15 others

What the payments were for

  • Food & beverage$4,14199%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,170 in reported general payments places this provider in the 60th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$84,478
Medicare patients
301
Services billed
608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide46$35,306
CreonLipase/Protease/Amylase21$21,216
Dexlansoprazole DrDexlansoprazole51$18,323
DexilantDexlansoprazole24$13,376
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates127$8,290
Mesalamine21$5,426
Colesevelam Hcl39$5,328
Pantoprazole Sodium338$4,962
PrevacidLansoprazole13$3,615
Mesalamine ErMesalamine19$2,287
Budesonide DrBudesonide12$956
Sucralfate41$789
Lubiprostone14$584
Lansoprazole20$583
Rabeprazole Sodium20$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,169$56,52267 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$286$13,37624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Springfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →